 |
8 Diseases |  |
1 Trial |
|
1 Trial |  |
95 News |  |
| 12» |
- CHF 6523 / Chiesi, nemiralisib (GSK2269557) / GSK
Animal models to assess potential post-inhalation irritant effects associated with inhaled drugs. (PS-9; Poster board no. 15) - May 31, 2024 - Abstract #ERS2024ERS_446;
No effect was observed with BDP. These data demonstrate that it is possible to assess the potential irritant effects associated with inhaled drugs using a head-out plethysmography applied to the inhalation system, thus helping in the selection of molecules devoid of such effects.
- || nemiralisib (GSK2269557) / GSK
Review, Journal: Efficacy of Nemiralisib in Chronic Obstructive Pulmonary Disease: A Systematic Review. (Pubmed Central) - May 23, 2024
In terms of safety, nemiralisib was generally well tolerated. Further trials are required to explore the efficacy of this drug.
- | nemiralisib (GSK2269557) / GSK
Journal: An open label trial of nemiralisib, an inhaled PI3 kinase delta inhibitor for the treatment of Activated PI3 kinase Delta Syndrome. (Pubmed Central) - Mar 16, 2023
P2
In this study investigating a small number of subjects with APDS, nemiralisib appeared to be safe and well-tolerated. However, data from this study do not support the hypothesis that inhaled treatment with nemiralisib would benefit patients with APDS.
- | Ukoniq (umbralisib) / TG Therap, nemiralisib (GSK2269557) / GSK, Tavalisse (fostamatinib) / Rigel, Kissei
Journal: Immune cells transcriptome-based drug repositioning for multiple sclerosis. (Pubmed Central) - Nov 8, 2022
6 candidate drugs targeting two or more hub targets (Fostamatinib, Copper, Artenimol, Phenethyl isothiocyanate, Aspirin and Zinc) were obtained...We obtained 69 candidate drugs targeting two target pathways. We found that applying candidate drugs that target both the "PI3K-Akt signaling pathway" and "Chemokine signaling pathway" (e.g., Nemiralisib and Umbralisib) or applying tyrosine kinase inhibitors (e.g., Fostamatinib) may be potential therapies for the treatment of MS.
- Zydelig (idelalisib) / Gilead
FUNCTIONAL SCREENING OF PI3K INHIBITORS STRATIFIES RESPONDERS TO IDELALISIB AND INDICATES DRUG CLASS ACTIVITY IN IDELALISIB-REFRACTORY CLL () - May 13, 2022 - Abstract #EHA2022EHA_1186;
Aims To characterize functional responses to 10 PI3Ki in CLL To study PI3Ki drug class activity in idelalisib-refractory CLL To investigate whether ex vivo drug sensitivity can predict in vivo treatment responses Methods CLL cells from patients that were treatment naïve (n=7), idelalisib refractory (n=9), or on idelalisib treatment (longitudinal samples from n=6 patients) were screened against 10 PI3Ki (buparlisib, compound 7n, copanlisib, duvelisib, idelalisib, nemiralisib, pictilisib, pilaralisib, umbralisib, ZSTK474), both alone and in combination with the B-cell lymphoma 2 (Bcl-2) antagonist venetoclax...Ex vivo drug testing on CLL cells from a patient who presented with relapsed disease after sequential treatment with FCR, ibrutinib, idelalisib and venetoclax revealed sensitivity to PI3Ki+venetoclax treatment...Conclusion Our findings indicate PI3Ki drug class activity in idelalisib-refractory CLL, and suggest that ex vivo drug sensitivity may guide precision medicine and predict treatment responses. These results warrant further testing in larger cohorts and in clinical trials.
- || nemiralisib (GSK2269557) / GSK
PK/PD data, Journal: Physiologically Based Pharmacokinetic Modelling of Inhaled Nemiralisib: Mechanistic Components for Pulmonary Absorption, Systemic Distribution, and Oral Absorption. (Pubmed Central) - Apr 26, 2022
These results warrant further testing in larger cohorts and in clinical trials. Fully mechanistic inhaled PBPK models such as the model described herein could be applied for cross molecule assessments with respect to lung retention and systemic exposure, both in terms of pharmacology and toxicology, and may facilitate clinical indication selection.
- || nemiralisib (GSK2269557) / GSK
Clinical, Journal: An Inhaled PI3Kδ Inhibitor Improves Recovery in Acutely Exacerbating COPD Patients: A Randomized Trial. (Pubmed Central) - Aug 13, 2021
P2
These data show that addition of nemiralisib to usual care delivers more effective recovery from an acute exacerbation and improves lung function parameters including siVaw and FEV. Although post-inhalation cough was identified, nemiralisib was otherwise well tolerated, providing a promising novel therapy for this acutely ill patient group.
- || nemiralisib (GSK2269557) / GSK
Clinical, Journal: Exploring PI3Kδ Molecular Pathways in Stable COPD and Following an Acute Exacerbation, Two Randomized Controlled Trials. (Pubmed Central) - Aug 13, 2021
We provide evidence for nemiralisib-evoked changes in neutrophil migration phenotype in stable COPD but not AECOPD, despite improving lung function in the latter group. We conclude that induced sputum can be used for measuring evidence of alteration of neutrophil phenotype in stable patients, and our study provides a data set of the sputum transcriptomic changes during recovery from AECOPD.
- || nemiralisib (GSK2269557) / GSK
Clinical, Journal: Nemiralisib in Patients with an Acute Exacerbation of COPD: Placebo-Controlled, Dose-Ranging Study. (Pubmed Central) - Aug 13, 2021
The addition of nemiralisib to standard-of-care treatment for 12 weeks did not improve lung function or re-exacerbations in patients with, and following an acute exacerbation of COPD. However, this study demonstrated that large clinical trials recruiting acutely exacerbating patients can successfully be conducted.
- | nemiralisib (GSK2269557) / GSK
Preclinical, Journal: Drug interactions for low dose inhaled nemiralisib - a case study integrating modelling, in vitro and clinical investigations. (Pubmed Central) - Jul 21, 2021
PBPK and static mechanistic models were also used to predict a negligible perpetrator DDI effect for nemiralisib on other P4503A4 substrates, including midazolam (a sensitive probe substrate of P4503A4) and theophylline (a narrow therapeutic index drug and another common comedication)...SIGNIFICANCE STATEMENT: This paper describes the integration of in silico, in vitro and clinical data to successfully discharge potential drug-drug interaction risks for a low dose inhaled drug. This work featured assessment of victim and perpetrator risks of drug transporters and cytochrome P450 (CYP) enzymes utilizing empirical and mechanistic approaches, combined with clinical data (drug interaction and human absorption, metabolism and pharmacokinetics), and physiologically based pharmacokinetic (PBPK) modelling approaches to facilitate bespoke risk assessment in target patient populations.
- AZD8154 / AstraZeneca, nemiralisib (GSK2269557) / GSK
[VIRTUAL] PI3Kγd Inhibitor, AZD8154, Demonstrates Improved Efficacious Profile Over PI3Kd Selective Inhibitor, GSK2269557, in a Rat Model of Asthma () - Mar 14, 2021 - Abstract #ATS2021ATS_4669;
Furthermore, these data suggest that AZD8154 may not trigger the increase in coughing which was observed for GSK557. Together these data indicate that AZD8154 may be an effective treatment for people suffering from asthma.
- || nemiralisib (GSK2269557) / GSK
Very elegant way from @GSK - Application of C–H Functionalization in the Development of a Concise and Convergent Route to the Phosphatidylinositol-3-kinase Delta Inhibitor Nemiralisib https://t.co/xMzbOBNYVp (Twitter) - Feb 10, 2021
- Trelegy Ellipta (fluticasone furoate/umeclidinium bromide/vilanterol) / GSK, Innoviva, Ellipta DPI (nemiralisib) / GSK
[VIRTUAL] Captain Study: Simultaneous Step-Up to High Dose Fluticasone Furoate and Addition of Umeclidinium for the Treatment of Inadequately Controlled Asthma (ATS 2020 Virtual) - Jul 6, 2020 - Abstract #ATSI2020ATS-I_316;
P3
Increasing FF dose and adding UMEC in a single step represents a therapeutic option for patients with asthma that are inadequately controlled on FF/VI 100/25 mcg. Funding GSK (study 205715/NCT02924688).
- ||| nemiralisib (GSK2269557) / GSK
Trial completion, Enrollment change: Safety, Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of Repeat Doses of Inhaled Nemiralisib in Patients With APDS/PASLI (clinicaltrials.gov) - Jun 22, 2020
P2, N=5, Completed, Sponsor: GlaxoSmithKline
Funding GSK (study 205715/NCT02924688). Active, not recruiting --> Completed | N=20 --> 5
- | Ellipta DPI (nemiralisib) / GSK
Clinical, PK/PD data, Journal: An innovative approach to characterize clinical ADME and pharmacokinetics of the inhaled drug nemiralisib using an intravenous microtracer combined with an inhaled dose, and an oral radiolabel dose in healthy male subjects. (Pubmed Central) - Jun 14, 2020
The work includes features such as intravenous [14C] tracer administration concomitant with an inhalation dose to describe pharmacokinetics, entero-test bile sampling to characterize biliary elimination pathways and a full metabolic profile in plasma and excreta. In addition we describe equations that can be used to estimate parameters such as fraction absorbed (Fabs), the proportion of drug escaping first pass extraction through the gut wall and liver (Fg and Fh) and hepatic extraction (Eh) which, to the authors knowledge, have never been published before.
- || Ellipta DPI (nemiralisib) / GSK
Clinical, PK/PD data, Journal: Safety, Tolerability, and Pharmacokinetics of a New Formulation of Nemiralisib Administered via a Dry Powder Inhaler to Healthy Individuals. (Pubmed Central) - May 19, 2020
P1
These data supported progression of nemiralisib to a Phase IIb study in patients with chronic obstructive pulmonary disease. ClinicalTrials.gov identifier: NCT03189589.
- || Ellipta DPI (nemiralisib) / GSK
Clinical, PK/PD data, Journal: Evaluation of the Safety, Tolerability, and Pharmacokinetics of GSK2269557 (Nemiralisib) Administered Via Dry Powder Inhaler to Healthy Japanese Subjects. (Pubmed Central) - Mar 24, 2020
Following 10 daily doses of 200, 500, and 700 μg nemiralisib, accumulation was observed, and the ratios (session 2, day 10:session 1) for Ro(AUC ) and R(C ) were 2.4-3.0 and 1.5-1.7, respectively. Steady state was achieved by 6-7 days, based on trough observed plasma drug concentration (C ) values.
- AZD8154 / AstraZeneca, Ellipta DPI (nemiralisib) / GSK
PI3Kγδ Inhibitor, AZD8154, Demonstrates Improved Efficacious Profile Over PI3Kδ Selective Inhibitor, GSK2269557, in a Rat Model of Asthma (PENNSYLVANIA CONVENTION CENTER, Hall D-E (200 Level), Area F - Poster Board P776) - Mar 15, 2020 - Abstract #ATS2020ATS_8629;
Steady state was achieved by 6-7 days, based on trough observed plasma drug concentration (C ) values. Abstract embargoed at this time.
- Trelegy Ellipta (fluticasone furoate/umeclidinium bromide/vilanterol) / GSK, Innoviva, Ellipta DPI (nemiralisib) / GSK
Captain Study: Simultaneous Step-Up to High Dose Fluticasone Furoate and Addition of Umeclidinium for the Treatment of Inadequately Controlled Asthma (PENNSYLVANIA CONVENTION CENTER, Room 120 A-C (100 Level)) - Mar 15, 2020 - Abstract #ATS2020ATS_3250;
P3
Increasing FF dose and adding UMEC in a single step represents a therapeutic option for patients with asthma that are inadequately controlled on FF/VI 100/25 mcg. Funding GSK (study 205715/NCT02924688).
- Ellipta DPI (nemiralisib) / GSK
Practical use of Ellipta, a once-daily, dry powder inhaler for children with asthma (Convention Center, 200 Level, Hall D) - Mar 1, 2020 - Abstract #AAAAI2020AAAAI_1085;
Funding GSK (study 205715/NCT02924688). Most children were able to use the once-daily Ellipta DPI correctly and easily, suggesting that the Ellipta DPI may simplify inhaler use for children with asthma in clinical practice.
- | nemiralisib (GSK2269557) / GSK
Enrollment closed: Safety, Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of Repeat Doses of Inhaled Nemiralisib in Patients With APDS/PASLI (clinicaltrials.gov) - Feb 27, 2020
P2, N=20, Active, not recruiting, Sponsor: GlaxoSmithKline
Most children were able to use the once-daily Ellipta DPI correctly and easily, suggesting that the Ellipta DPI may simplify inhaler use for children with asthma in clinical practice. Recruiting --> Active, not recruiting
- |||||| nemiralisib (GSK2269557) / GSK
Trial termination: Dose Finding Study of Nemiralisib (GSK2269557) in Subjects With an Acute Moderate or Severe Exacerbation of Chronic Obstructive Pulmonary Disease (COPD) (clinicaltrials.gov) - Feb 10, 2020
P2b, N=943, Terminated, Sponsor: GlaxoSmithKline
Recruiting --> Active, not recruiting Completed --> Terminated; Unfavourable benefit:risk
- || Ellipta DPI (nemiralisib) / GSK
Clinical, PK/PD data, Journal: Relationship between pharmacokinetics and pharmacodynamic responses in healthy smokers informs a once daily dosing regimen for nemiralisib. (Pubmed Central) - Jan 1, 2020
Comparison of drug levels in plasma and reductions in sputum PIP3 show a direct relationship between exposure and PIP3 reduction. In conclusion, these results demonstrate target engagement upon treatment with inhaled nemiralisib and provide confidence for a once-daily dosing regimen.
- || GSK2292767 / GSK
Clinical, PK/PD data, Journal: Translation of inhaled drug optimization strategies into clinical pharmacokinetics and pharmacodynamics using GSK2292767A, a novel inhaled PI3Kδ inhibitor. (Pubmed Central) - Jan 1, 2020
BAL analysis confirmed presence of GSK2292767A in lung at 24 h, consistent with the preclinical lung retention profile. Despite good lung retention, target engagement was only present at 3 h. This exposure-response disconnect is an important observation for future inhaled drug design strategies considering low solubility to drive lung retention.
- | nemiralisib (GSK2269557) / GSK
Clinical, PK/PD data, Journal: A multicentre, randomised, double-blind, placebo-controlled, crossover study to investigate the efficacy, safety, tolerability and pharmacokinetics of repeat doses of inhaled nemiralisib in adults with persistent, uncontrolled asthma. (Pubmed Central) - Oct 8, 2019
Further studies will investigate the potential efficacy of nemiralisib in patients with asthma with other specific more severe phenotypes, including those who are colonised with bacteria and frequently exacerbate. .
- | nemiralisib (GSK2269557) / GSK
Clinical, PK/PD data, Journal: Safety, Tolerability, and Pharmacokinetics of Single and Repeat Doses of Nemiralisib Administered via the Ellipta Dry Powder Inhaler to Healthy Subjects. (Pubmed Central) - Sep 7, 2019
P1
Plasma pharmacokinetic variables were well defined, and charcoal block data indicate that ∼23% of the total systemic exposure after inhalation from Ellipta was attributable to orally absorbed drug. ClinicalTrials.gov identifier: NCT02691325.
- | nemiralisib (GSK2269557) / GSK
Trial completion date, Trial primary completion date: Safety, Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of Repeat Doses of Inhaled Nemiralisib in Patients With APDS/PASLI (clinicaltrials.gov) - Aug 9, 2019
P2, N=20, Recruiting, Sponsor: GlaxoSmithKline
ClinicalTrials.gov identifier: NCT02691325. Trial completion date: Feb 2020 --> May 2020 | Trial primary completion date: Feb 2020 --> May 2020
- |||| nemiralisib (GSK2269557) / GSK
Trial completion: Dose Finding Study of Nemiralisib (GSK2269557) in Subjects With an Acute Moderate or Severe Exacerbation of Chronic Obstructive Pulmonary Disease (COPD) (clinicaltrials.gov) - Apr 16, 2019
P2b, N=948, Completed, Sponsor: GlaxoSmithKline
Trial completion date: Feb 2020 --> May 2020 | Trial primary completion date: Feb 2020 --> May 2020 Active, not recruiting --> Completed
- | nemiralisib (GSK2269557) / GSK
Enrollment closed: Dose Finding Study of Nemiralisib (GSK2269557) in Subjects With an Acute Moderate or Severe Exacerbation of Chronic Obstructive Pulmonary Disease (COPD) (clinicaltrials.gov) - Aug 13, 2018
P2b, N=1250, Active, not recruiting, Sponsor: GlaxoSmithKline
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- | nemiralisib (GSK2269557) / GSK
Biomarker, Trial completion, Trial completion date, Trial primary completion date: A Study to Evaluate the Safety, Efficacy and Changes in Induced Sputum and Blood Biomarkers Following Daily Repeat Doses of Inhaled GSK2269557 in Chronic Obstructive Pulmonary Disease (COPD) Subjects With Acute Exacerbation (clinicaltrials.gov) - Jul 17, 2018
P2, N=46, Completed, Sponsor: GlaxoSmithKline
Recruiting --> Active, not recruiting Active, not recruiting --> Completed | Trial completion date: Oct 2018 --> Jun 2018 | Trial primary completion date: Oct 2018 --> Jun 2018
- | nemiralisib (GSK2269557) / GSK
Biomarker, Enrollment closed: A Study to Evaluate the Safety, Efficacy and Changes in Induced Sputum and Blood Biomarkers Following Daily Repeat Doses of Inhaled GSK2269557 in Chronic Obstructive Pulmonary Disease (COPD) Subjects With Acute Exacerbation (clinicaltrials.gov) - Apr 18, 2018
P2, N=45, Active, not recruiting, Sponsor: GlaxoSmithKline
Active, not recruiting --> Completed | Trial completion date: Oct 2018 --> Jun 2018 | Trial primary completion date: Oct 2018 --> Jun 2018 Recruiting --> Active, not recruiting
- | nemiralisib (GSK2269557) / GSK
Trial completion: A Study to Evaluate the Effect of Itraconazole on the Pharmacokinetics (PK) of Nemiralisib (clinicaltrials.gov) - Mar 12, 2018
P1, N=20, Completed, Sponsor: GlaxoSmithKline
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- nemiralisib (GSK2269557) / GSK
Enrollment closed: A Study to Evaluate the Effect of Itraconazole on the Pharmacokinetics (PK) of Nemiralisib (clinicaltrials.gov) - Feb 12, 2018
P1, N=20, Active, not recruiting, Sponsor: GlaxoSmithKline
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- nemiralisib (GSK2269557) / GSK
Enrollment open: A Study to Evaluate the Effect of Itraconazole on the Pharmacokinetics (PK) of Nemiralisib (clinicaltrials.gov) - Feb 6, 2018
P1, N=20, Recruiting, Sponsor: GlaxoSmithKline
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- nemiralisib (GSK2269557) / GSK
Trial completion: Absorption & Elimination of Radiolabelled GSK2269557 (clinicaltrials.gov) - Jan 12, 2018
P1, N=6, Completed, Sponsor: GlaxoSmithKline
Not yet recruiting --> Recruiting Recruiting --> Completed
- | nemiralisib (GSK2269557) / GSK
New P1 trial: A Study to Evaluate the Effect of Itraconazole on the Pharmacokinetics (PK) of Nemiralisib (clinicaltrials.gov) - Jan 11, 2018
P1, N=20, Not yet recruiting, Sponsor: GlaxoSmithKline
- | nemiralisib (GSK2269557) / GSK
Biomarker, Enrollment change, Trial primary completion date: A Study to Evaluate the Safety, Efficacy and Changes in Induced Sputum and Blood Biomarkers Following Daily Repeat Doses of Inhaled GSK2269557 in Chronic Obstructive Pulmonary Disease (COPD) Subjects With Acute Exacerbation (clinicaltrials.gov) - Dec 6, 2017
P2, N=45, Recruiting, Sponsor: GlaxoSmithKline
Recruiting --> Completed N=35 --> 45 | Trial primary completion date: Apr 2018 --> Oct 2018
- |||| nemiralisib (GSK2269557) / GSK
Enrollment open: Dose Finding Study of Nemiralisib (GSK2269557) in Subjects With an Acute Moderate or Severe Exacerbation of Chronic Obstructive Pulmonary Disease (COPD) (clinicaltrials.gov) - Dec 6, 2017
P2b, N=1250, Recruiting, Sponsor: GlaxoSmithKline
N=35 --> 45 | Trial primary completion date: Apr 2018 --> Oct 2018 Not yet recruiting --> Recruiting
- nemiralisib (GSK2269557) / GSK
Enrollment open: Absorption & Elimination of Radiolabelled GSK2269557 (clinicaltrials.gov) - Nov 27, 2017
P1, N=6, Recruiting, Sponsor: GlaxoSmithKline
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- |||||| nemiralisib (GSK2269557) / GSK
New P2b trial: Dose Finding Study of Nemiralisib (GSK2269557) in Subjects With an Acute Moderate or Severe Exacerbation of Chronic Obstructive Pulmonary Disease (COPD) (clinicaltrials.gov) - Nov 17, 2017
P2b, N=1250, Not yet recruiting, Sponsor: GlaxoSmithKline
- nemiralisib (GSK2269557) / GSK
New P1 trial: Absorption & Elimination of Radiolabelled GSK2269557 (clinicaltrials.gov) - Oct 20, 2017
P1, N=6, Not yet recruiting, Sponsor: GlaxoSmithKline
- | nemiralisib (GSK2269557) / GSK
Trial completion: Safety, Tolerability and Pharmacokinetics (PK) Study of GSK2269557 in Healthy Subjects (clinicaltrials.gov) - Aug 6, 2017
P1, N=12, Completed, Sponsor: GlaxoSmithKline
Not yet recruiting --> Recruiting Recruiting --> Completed
- nemiralisib (GSK2269557) / GSK
Enrollment open: Safety, Tolerability and Pharmacokinetics (PK) Study of GSK2269557 in Healthy Subjects (clinicaltrials.gov) - Jun 27, 2017
P1, N=12, Recruiting, Sponsor: GlaxoSmithKline
Recruiting --> Completed Not yet recruiting --> Recruiting
- | nemiralisib (GSK2269557) / GSK
New P1 trial: Safety, Tolerability and Pharmacokinetics (PK) Study of GSK2269557 in Healthy Subjects (clinicaltrials.gov) - Jun 16, 2017
P1, N=12, Not yet recruiting, Sponsor: GlaxoSmithKline
- nemiralisib (GSK2269557) / GSK
Biomarker, Trial primary completion date: A Study to Evaluate the Safety, Efficacy and Changes in Induced Sputum and Blood Biomarkers Following Daily Repeat Doses of Inhaled GSK2269557 in Chronic Obstructive Pulmonary Disease (COPD) Subjects With Acute Exacerbation (clinicaltrials.gov) - Mar 9, 2017
P2, N=35, Recruiting, Sponsor: GlaxoSmithKline
Not yet recruiting --> Recruiting Trial primary completion date: Feb 2017 --> Apr 2018
- | nemiralisib (GSK2269557) / GSK
Trial completion: Study to Evaluate Safety, Tolerability and Pharmacokinetics of GSK2269557 to Japanese Healthy Subjects (clinicaltrials.gov) - Jan 18, 2017
P1, N=36, Completed, Sponsor: GlaxoSmithKline
Trial primary completion date: Feb 2017 --> Apr 2018 Active, not recruiting --> Completed
- nemiralisib (GSK2269557) / GSK
Enrollment closed: Study to Evaluate Safety, Tolerability and Pharmacokinetics of GSK2269557 to Japanese Healthy Subjects (clinicaltrials.gov) - Dec 24, 2016
P1, N=36, Active, not recruiting, Sponsor: GlaxoSmithKline
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- nemiralisib (GSK2269557) / GSK
Enrollment open, Trial primary completion date: Safety, Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of Repeat Doses of Inhaled Nemiralisib in Patients With APDS/PASLI (clinicaltrials.gov) - Dec 20, 2016
P2, N=5, Recruiting, Sponsor: GlaxoSmithKline
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting | Trial primary completion date: Aug 2018 --> Dec 2018
- | nemiralisib (GSK2269557) / GSK
New P1 trial: Study to Evaluate Safety, Tolerability and Pharmacokinetics of GSK2269557 to Japanese Healthy Subjects (clinicaltrials.gov) - Dec 19, 2016
P1, N=36, Active, not recruiting, Sponsor: GlaxoSmithKline
- | nemiralisib (GSK2269557) / GSK
Trial completion: A Study to Investigate the Efficacy, Safety, and Tolerability of Repeat Doses of Inhaled GSK2269557 in Adults With Persistent, Uncontrolled Asthma (clinicaltrials.gov) - Nov 10, 2016
P2, N=50, Completed, Sponsor: GlaxoSmithKline
Not yet recruiting --> Recruiting | Trial primary completion date: Aug 2018 --> Dec 2018 Recruiting --> Completed